Research programme: angiogenesis inhibitors - Bausch & Lomb/PTC Therapeutics

Drug Profile

Research programme: angiogenesis inhibitors - Bausch & Lomb/PTC Therapeutics

Alternative Names: Research programme: eye disorders therapy - Bausch & Lomb/PTC Therapeutics

Latest Information Update: 27 Jul 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PTC Therapeutics
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Macular degeneration

Most Recent Events

  • 27 Oct 2007 Bausch and Lomb has been acquired by Warburg Pincus
  • 12 Dec 2005 Preclinical trials in Macular degeneration in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top